State Treasurer State of Michigan cut its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 10.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,500 shares of the biotechnology company’s stock after selling 2,500 shares during the period. State Treasurer State of Michigan’s holdings in Aurinia Pharmaceuticals were worth $138,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in AUPH. Jane Street Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at about $155,000. Two Sigma Securities LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter worth about $240,000. TD Asset Management Inc. purchased a new position in Aurinia Pharmaceuticals during the first quarter worth about $241,000. Quantbot Technologies LP purchased a new position in Aurinia Pharmaceuticals during the first quarter worth about $275,000. Finally, Hikari Power Ltd purchased a new position in Aurinia Pharmaceuticals during the first quarter worth about $440,000. Institutional investors own 29.48% of the company’s stock.
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded down 3.3681% on Thursday, reaching $5.7496. The company had a trading volume of 792,979 shares. Aurinia Pharmaceuticals Inc has a 12 month low of $1.74 and a 12 month high of $10.54. The stock’s market cap is $478.78 million. The stock has a 50-day moving average price of $6.37 and a 200-day moving average price of $6.14.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%. Analysts predict that Aurinia Pharmaceuticals Inc will post ($0.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2800707/aurinia-pharmaceuticals-inc-nasdaqauph-stake-decreased-by-state-treasurer-state-of-michigan.html.
A number of research analysts recently issued reports on AUPH shares. Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, April 21st. HC Wainwright decreased their price objective on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 18th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Vetr downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price objective for the company. in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $9.28.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.